What it's for (Indications)
- Cefotaxime, a broad-spectrum third-generation cephalosporin antibiotic, is indicated for the treatment of various serious bacterial infections caused by susceptible organisms.
- Its broad spectrum includes many Gram-positive and Gram-negative bacteria.
- Key indications encompass respiratory tract infections such as pneumonia and bronchitis, complicated urinary tract infections, severe skin and soft tissue infections, intra-abdominal infections including peritonitis, gynecological infections, bone and joint infections, and bacterial meningitis, particularly in children and adults.
- It is also utilized in the management of septicemia and endocarditis.
- Furthermore, cefotaxime can be employed as prophylaxis in surgical procedures where there is a high risk of infection.
- Its efficacy against multi-drug resistant strains of some bacteria makes it a valuable therapeutic option in clinical settings, especially when empirical therapy for severe infections is required before definitive susceptibility results are available.
- Appropriate cultures and susceptibility testing should be performed to guide and confirm therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cefotaxime must be individualized based on the severity of the infection, the susceptibility of the causative organism, the patient's age, weight, and renal function. For adults and adolescents, the typical dosage ranges from 1 to 2 grams administered intravenously (IV) or intramuscularly (IM) every 8 to 12 hours. For severe infections, the dosage may be increased to 2 grams every 6 to 8 hours, with a maximum daily dose generally not exceeding 12 grams. In cases of bacterial meningitis, higher doses such as 2 grams IV every 4 to 6 hours are often necessary. Pediatric dosing is calculated based on body weight, commonly 50 to 180 mg/kg/day divided into 4 to 6 equal doses, depending on the infection's severity. Patients with impaired renal function require significant dose adjustments to prevent accumulation and potential toxicity; creatinine clearance levels should guide these modifications. It is crucial to adhere strictly to prescribed dosages and administration schedules to ensure optimal therapeutic outcomes and minimize the development of antibiotic resistance. |
Safety & Warnings
Common Side Effects
- Like all antibiotics, cefotaxime can cause a range of side effects, though not all patients will experience them.
- Common adverse reactions include pain, tenderness, or inflammation at the injection site (for IM administration), and phlebitis or thrombophlebitis following IV administration.
- Gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain are also frequently reported.
- Hypersensitivity reactions can occur, ranging from mild skin rashes (e.
- g.
- , urticaria, pruritus) to severe and potentially life-threatening anaphylaxis, characterized by bronchospasm, angioedema, and hypotension.
- Hematologic abnormalities, including eosinophilia, leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and hemolytic anemia, are possible, usually reversible upon discontinuation.
- Neurological effects like seizures, particularly with high doses in patients with renal impairment, have been observed.
- Superinfections, especially candidiasis (oral thrush, vaginal yeast infections) and *Clostridioides difficile*-associated diarrhea (CDAD), which can range from mild diarrhea to severe pseudomembranous colitis, are important considerations.
- Liver enzyme elevations (transaminases) and renal dysfunction (transient increases in BUN and serum creatinine) may also occur.
- Any persistent or severe side effects should be reported to a healthcare professional immediately.
Serious Warnings
- Black Box Warning: Cefotaxime does not carry a formal FDA Black Box Warning. However, several serious safety considerations must be meticulously observed during its administration, reflecting high-risk factors inherent to its pharmacological class. Foremost among these is the potential for severe hypersensitivity reactions, including anaphylaxis, which can be fatal. Patients should be thoroughly screened for a history of allergic reactions to cefotaxime, other cephalosporins, penicillins, or other beta-lactam antibiotics prior to initiating therapy. Cross-reactivity between penicillins and cephalosporins, while infrequent, necessitates extreme caution, particularly in individuals with a history of immediate-type severe penicillin allergy. Furthermore, treatment with nearly all antibacterial agents, including cefotaxime, has been linked to Clostridioides difficile-associated diarrhea (CDAD), which can manifest with varying degrees of severity, from mild diarrhea to life-threatening pseudomembranous colitis. This adverse effect can occur during or several months post-treatment and requires prompt and accurate diagnosis in patients presenting with diarrhea following antibiotic exposure. Renal impairment may necessitate significant dosage adjustment to prevent drug accumulation and potential neurotoxic effects, such as seizures, especially in individuals with pre-existing renal dysfunction or those receiving high doses.
- Cefotaxime should be used with extreme caution in patients with a known history of hypersensitivity to cephalosporins, penicillins, or other beta-lactam antibiotics due to the risk of cross-allergenicity, which can be severe and fatal.
- Before initiating therapy, a thorough inquiry about previous allergic reactions should be made.
- If an allergic reaction occurs, the drug should be discontinued immediately, and appropriate emergency treatment initiated.
- Severe *Clostridioides difficile*-associated diarrhea (CDAD), ranging from mild to fatal colitis, has been reported with nearly all antibacterial agents, including cefotaxime.
- It is important to consider this diagnosis in patients who present with diarrhea subsequent to antibiotic administration.
- Dosage adjustments are mandatory in patients with impaired renal function to prevent accumulation and potential toxicity, including seizures.
- Prolonged use of cefotaxime may result in the overgrowth of non-susceptible organisms, necessitating careful monitoring for superinfections.
- Concurrent administration of cefotaxime with aminoglycosides should be approached with caution due to the potential for increased nephrotoxicity.
- Although animal studies have not revealed teratogenic effects, cefotaxime should be used during pregnancy only if clearly needed.
- It is excreted in breast milk in small quantities, so caution is advised when administered to a nursing mother.
How it Works (Mechanism of Action)
Cefotaxime exerts its potent bactericidal effect by interfering with bacterial cell wall synthesis. As a beta-lactam antibiotic, its primary mechanism involves binding to and inactivating penicillin-binding proteins (PBPs), which are enzymes located on the inner membrane of the bacterial cell wall. These PBPs are crucial for the final stages of peptidoglycan synthesis, specifically the transpeptidation reaction that cross-links peptidoglycan strands, providing structural rigidity to the bacterial cell wall. By irreversibly acylating the active site of these transpeptidases (a type of PBP), cefotaxime prevents the formation of an intact and functional cell wall. This disruption leads to the osmotic instability of the bacterial cell, ultimately resulting in cell lysis and death. Cefotaxime is generally resistant to hydrolysis by many common beta-lactamases produced by both Gram-positive and Gram-negative bacteria, which contributes to its broad spectrum of activity and clinical utility against resistant strains, though extended-spectrum beta-lactamases (ESBLs) can still hydrolyze it. The drug's affinity for specific PBPs, particularly PBP-3, is a key determinant of its antibacterial spectrum and efficacy.